Consistent with previous enrichment analysis of DEGs, SLC24A2 showed the abnormal expression in 17 cancers including bladder cancer (BLCA), prostate cancer (PRAD), and lung cancer (LUAD and LUSC) (Figure 6(a)). Here, SLC24A2 is linked to cancer.